Effects of an LCHF/ketogenic diet on symptoms, anxiety, depression, and QoL in Parkinson’s disease

Not Applicable

Completed

• Conditions: Parkinson's Disease, Neurodegenerative Diseases; Mental and Behavioural Disorders; Parkinson's Disease

• Registration Number: ISRCTN80586209
• Lead Sponsor: Colorado Parkinson Foundation

Brief Summary

2022 Results article in https://doi.org/10.2217/nmt-2021-0033 (added 09/08/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-05
• Study Completion: 2021-09-30
• Last Update Posted: 22 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. BMI >18.5
2. Hoehn-Yahr Stages I-IV
3. Aged 50 to 85 years
4. Have received permission from their Primary Care Provider to participate in the study and, if diabetic, have received a written Insulin Sliding Scale to be used during the study
5. Are cognitively able to follow the dietary plan
6. Are able to read, speak, and understand English
7. Provide written informed consent to participate in the trial

Exclusion Criteria

None

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. The course of Parkinson's disease measured using the Unified Parkinson's Disease Rating Scale (UPDRS) Parts 1 to 4 at baseline and 12 weeks<br> 2. Anxiety measured using the Parkinson’s Anxiety Scale (PAS) at baseline and 12 weeks<br> 3. Depression measured using the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R-20) at baseline and 12 weeks<br> 4. Lipid profile assessed through blood markers including HgA1C, Triglycerides, LDL, CRP, and HDL taken at baseline and 12 weeks<br>

Secondary Outcome Measures

Name	Time	Method
Mental, physical, and social quality of life assessed through qualitative analysis of these themes from audio-recorded structured interviews at baseline and 12 weeks